Department of Hematology, Oncology and Palliative Care, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany
Celine Lugnier , Sarah Foerster , Anna-Lena Kraeft , Inke Sabine Feder , Jens Christmann , Eleni Kourti , Oliver Overheu , Sabine Sommerlatte , Waldemar Uhl , Martin Schoenlein , Vivian Rosery , Christoph Biermann , Lothar Müller , Olaf Schoffer , Jochen Schmitt , Dominik Paul Modest , Volker Heinemann , Jan Schildmann , Anke C. Reinacher-Schick , Andrea Tannapfel
Background: CRC still is one of the leading causes of cancer related death though prognosis has improved through guideline based management. The COVID-19 pandemic lead to re-allocation of resources subordinating all sections of care for CRC patients. We present data on changes of CRC care during the pandemic from 22 German AIO CC and our high volume Institute of Pathology (pathology). Methods: Data was collected retrospectively comparing the months (mo) of the first wave (fw) (4-6/2020) and second wave (sw) (11-12/2020) of the pandemic with corresponding periods (cp) in 2019 focusing on the number of precancerous (ICD-O/0+2) and malignant (ICD-O/3+6) colorectal lesions (CRL) diagnosed by our pathology, the number/stage of primary diagnoses (PD) and the number of surgeries (surg) at AIO CC. There, quality criteria of CRC care were also assessed (number of PD discussed within a multidisciplinary tumor board (tb), received social service (soc)/ psychological (psy) counseling or recruited into a clinical trial). Statistical analysis was performed using students t-test for paired data. Results: Numbers of CRL detected upon histology (row 1-3), number of cases, surg and quality criteria from AIO CC (row 4-9) are displayed in the table. We saw a dip in diagnosed CRL and number of surg (p=0.007) only during fw, whereas PD dipped significantly in both waves. A significant reduction in diagnosis of stage III CRC was detected for 2019 vs. 2020 (p=0.001), not for other stages. Quality criteria showed a significant reduction in clinical trial inclusion, a small dip in soc/psy counseling and persistently high tb presentation. Conclusions: We detected a significant decrease of premalignant lesions and primary cancers during the first year of the pandemic which may impact cancer mortality in the future. Certified German CC provided CRC care with significant reduction in clinical trial inclusion only, suggesting high stability of established certified cancer care infrastructure.
2019 total | 2020 total | fw/cp 2019 | fw 2020 | fw p= | sw/cp 2019 | sw 2020 | w p= | 2019/20 p= | |
---|---|---|---|---|---|---|---|---|---|
Total (pathology) | 30794 | 29901 | 2531 | 2122 | 2462 | 2390 | |||
ICD-O/0+2 | 27848 | 27046 | 2294 | 1927 | 2250 | 2161 | |||
ICD-O/3+6 | 2848 | 2750 | 233 | 191 | 206 | 224 | |||
PD (AIO CC) | 2322 | 1995 | 8.5 | 6.8 | 0.004 | 8.4 | 5.7 | 0.005 | <0.001 |
surg | 1604 | 1505 | 7.4 | 5.5 | 0.007 | 7 | 5.6 | 0.23 | 0.003 |
trial | 313 | 160 | 2.9 | 1.9 | 0.06 | 2.6 | 2 | 0.3 | <0.001 |
%/PD | 42.93 | 27.77 | 41.28 | 27.59 | 37.90 | 29.96 | |||
tb | 872 | 792.76 | 6.6 | 4.9 | 0.06 | 6.5 | 5.6 | 0.26 | 0.18 |
%/PD | 94.44 | 67 | 92.02 | 94.25 | 97.16 | 92.48 | |||
psy | 417 | 354 | 3.1 | 2.3 | 0.1 | 3.3 | 2.9 | 0.4 | 0.04 |
%/PD | 47.48 | 42.83 | 45.97 | 44.46 | 47.31 | 37.35 | |||
soc | 611 | 521 | 4.9 | 3.7 | 0.08 | 5.2 | 3.6 | 0.03 | 0.012 |
%/PD | 63.31 | 63.31 | 64.93 | 63.93 | 78.08 | 53.97 |
Numbers in column fw/ sw, 2019/ 2020 represent the mean numbers of cases per mo (1-3) or per mo and site (4-9).
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Quality Care Symposium
First Author: Joshua Ling
2023 ASCO Annual Meeting
First Author: Ahmed Abdelhakeem
2023 ASCO Annual Meeting
First Author: Mark Bilinyi Ulanja
2024 ASCO Annual Meeting
First Author: Yoanna S. Pumpalova